Graft-versus-host disease (GVHD) is a T cell-mediated complication of allogeneic hematopoietic stem cell transplantation (HSCT), and despite advances in immunosuppression, remains a major cause of transplantationrelated morbidity and mortality.
and selection of primary lymphocytes. We demonstrate that leukemic and primary T cells can be efficiently transduced and highly enriched under conditions that should be readily adaptable for clinical use. T cells carrying HSV-TKSR39 were inhibited by exposure to ganciclovir at concentrations an order of magnitude below those required for wild-type HSV-TK. The less toxic agent aciclovir also eliminated T cells transduced with HSV-TKSR39 (but not HSV-TK), underlining the increased therapeutic potential of the mutant suicide gene system in the bone marrow transplantation setting.
Gene Therapy (2002) 9, 824-827. DOI: 10.1038/sj/gt/3301690 are poor substrates for mammalian nucleoside kinases, but are efficiently phosphorylated to the monophosphate form by HSV-TK. Cellular kinases mediate subsequent metabolism to produce toxic triphosphate derivatives that become incorporated into host cell DNA, leading to the death of actively dividing cells. 9 Bonini et al 7 reported the results from the first clinical trials using the HSV-TK/ganciclovir system for the management of GVHD following bone marrow transplantation (BMT). Twelve patients who had relapsed following allogeneic BMT or developed Epstein-Barr virus induced lymphoproliferative disease after T cell-depleted bone marrow transplantation were treated with infusions of donor T cells carrying HSV-TK. The transduced cells mediated anti-tumor effects in five patients and were detectable in some patients for up to 12 months. GVHD was effectively controlled in three of these five patients by the selective elimination of active T cells using ganciclovir. One case of chronic GVHD was only partially responsive to ganciclovir, and vector-related limitations included evidence of an immune response against the transgenes in two patients. 10 The group has now treated over 40 patients using this strategy, but results have yet to be fully evaluated. 11 Tiberghien et al 8 used HSV-TK transduced T cell infusions to prevent leukemic relapse in 14 patients undergoing BMT for haematological malignancy. Three patients developed acute GVHD and treatment with ganciclovir was successful in two, whilst the third required additional therapy with steroids. One patient developed chronic GVHD and also responded to ganciclovir. A 825 wider, multi-center collaborative trial is currently underway in Europe to further assess the strategy in patients undergoing HSCT for CML and other hematological malignancies. These initial studies have demonstrated the potential usefulness of this strategy, but have also highlighted limitations including possible downregulation of HSV-TK expression and resistance to GCVinduced elimination.
To overcome some of these problems we have generated retroviral vectors incorporating the spleen focus forming virus (SFFV) LTR which benefits from a modified U3 region and primer binding site for enhanced hematopoietic cell tropism for and reduced transgene silencing. 12 We demonstrated faithful and stable expression of two proteins from a single bicistronic construct in dual reporter vectors in which the internal ribosomal entry sequence (IRES) from the encephalomyocarditis virus 13 was used to link two marker proteins, enhanced green fluorescent protein (eGFP) 14 and the low affinity nerve growth factor receptor (⌬LNGFR) (Figure 1a ). 15 Subsequently, HSV-TK and the recently described enhanced mutant HSV-TKSR39 16 were cloned in place of eGFP and compared in leukemic T cell lines and primary T cells (Figure 1b ). Target cells were transduced in plates precoated with retronectin, 17 using viral supernatant produced by the mouse fibroblast packaging cell line PG13 (providing the gibbon ape leukemia virus envelope 18 or the human FLYRD18 packaging line (providing the feline endogenous virus envelope, RD114 19 ) according to the protocol outlined in Figure 2 . Primary peripheral blood mononuclear cells (PBMCs) required prestimulation for 48-72 h in stimulator plates coated with monoclonal antibodies against CD3 and CD28. Transduced cells could be readily detected using monoclonal antibody to ⌬LNGFR and enriched by magnetic bead sorting and expression of 
⌬LNGFR was stable for over 120 days in Jurkat T cells analyzed by serial flow cytometry (data not shown).
Leukemic cells were useful targets for characterizing HSV-TK and HSV-TKSR39 function. Transduction efficiencies of up to 90% were observed after two rounds of virus exposure using either the GALV or RD114 envelope systems. Equivalence of expression of wild-type and mutant HSV-TK protein was confirmed by Western blot analysis using polyclonal rabbit anti-HSV-TK sera. 20 Cells were exposed to a wide range of prodrug concentrations and survival was assessed as a function of mitochondrial activity (MTT assay 21 using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and is expressed as a percentage of control wells that did not receive GCV/ACV. Cells carrying HSV-TK SR39 were susceptible at concentrations of GCV an order of magnitude lower than for HSV-TK (Figure 3a) . All groups, including those expressing eGFP as the control group were affected at the highest concentrations of GCV. Only HSV-TKSR39 transduction rendered cells susceptible to ACV ( Figure  3b ) and this may be highly relevant in clinical practice for patients unable to tolerate the more toxic agent, GCV.
Primary PBMCs (0.5 × 10 6 /ml) were stimulated according to the protocol shown ( Figure 2 ) using retroviral constructs expressing the dual reporter gene or HSV-TK or HSV-TKSR39. After 48-72 h of pre-stimulation the cells were highly activated, with over 90% of the cells expressing CD3 and CD25, and preferential expansion of the CD8 + subset was consistently observed. Transduction efficiencies between 25-50% were observed and cells could be enriched on the basis of ⌬LNGFR expression to greater than 90% purity. T cells were resuspended at 0.5 × 10 6 /ml in triplicate and exposed to GCV for 4 days, before analysis using the MTT assay. Cells expressing HSV-TKSR39 were markedly inhibited at concentrations of GCV below 1 M in contrast to cells transduced with wild-type HSV-TK, which were only inhibited at higher concentrations ( Figure 4 ). The ⌬LNGFR negative fraction of T cells (ie the non-transduced cell fraction) was retained after Mini-Macs enrichment of transduced cells and did not exhibit sensitivity to GCV despite being highly activated and actively proliferating. Using trypan blue, no living cells were visible on microscopy of the cultures treated at the higher doses of GCV and the residual activity detected by the MTT assay (10-20%) may have been an artifact caused by the presence of degenerating cellular material as reported previously. 20 There have been reports of transduced T cells resistant to GCV that may have received truncated forms of the HSV-TK gene. 21 We have not detected these alternative splice variant forms of HSV-TK or HSV-TKSR39, and it is likely that this phenomenon is related to specific packaging cell lines and retroviral constructs.
HSV-TK mutants were originally generated using random sequence mutagenesis to create a large library of enzymes with substitutions at the putative nucleoside binding site. 20, 22, 23 Six amino acid changes at or near the active site enhance prodrug conversion through shifts in the catalytically active residues. The mutant HSV-TKSR39, with five amino acid substitutions between residues 158-161 and 168-169 compared with wild-type, appears to be the most effective mutant in vitro and in animal tumor models. 16 This is the first study investigating the feasibility of using HSV-TKSR39 for T cell suicide gene therapy and the results demonstrate effective suicide at concentrations of GCV below 1 M, concentrations at which the drug is unlikely to cause significant marrow suppression. Effective, selective elimination of T cells mediating GVHD using non-toxic concentrations of prodrugs could ultimately obviate the need for immunosuppressive therapy following HSCT and broaden the applications of mismatched allogeneic transplants. Realization of these goals is moving closer with the advent of new vectors and enhanced suicide gene systems based on HSV-TKSR39.
